VC firm
Negev Capital
- Investor type
- VC
- Investing status
- Not investingas of 2026-09-21Source (opens in a new tab)
Claim, correct or request removal
Record updated 30 September 2026
About
Negev Capital is a $30M+ biotech venture fund.
Investment approach
- Thesis
- Negev Capital was founded on the conviction that psychedelic-derived and novel neuropsychiatric compounds would become a mainstream therapeutic category. The fund's exits to AbbVie and Otsuka validated that thesis. Today, through Negev Labs and our active portfolio, we continue to build at the intersection of neuroscience innovation and clinical drug development.Source (opens in a new tab)
- Investing status notes
- Fully Invested
Programs
Loading relationship preview